Diabetes Care:高敏CRP可区分糖尿病亚型

2011-07-13 MedSci原创 MedSci原创

  英国一项研究表明,肝细胞核因子1-α-基因突变引起的年轻的成年发病型糖尿病(HNF1A - MODY)患者的高敏C反应蛋白(hs-CRP)水平低于其他类型的糖尿病患者,hs-CRP可能成为选择需进行诊断性HNF1A基因检测患者的生物标志物。该研究6月23日在线发表于《糖尿病护理》(Diabetes Care)杂志。   HNF1A-MODY常被误诊为1型糖尿病或2型糖尿病。新近研究发现,HN

  英国一项研究表明,肝细胞核因子1-α-基因突变引起的年轻的成年发病型糖尿病(HNF1A - MODY)患者的高敏C反应蛋白(hs-CRP)水平低于其他类型的糖尿病患者,hs-CRP可能成为选择需进行诊断性HNF1A基因检测患者的生物标志物。该研究6月23日在线发表于《糖尿病护理》(Diabetes Care)杂志。

  HNF1A-MODY常被误诊为1型糖尿病或2型糖尿病。新近研究发现,HNF1A-MODY患者的hs-CRP水平低于1型糖尿病患者、2型糖尿病患者或葡萄糖激酶(GCK)- MODY患者。此项研究期望在大样本受试者及其他MODY亚型患者中重复这些发现。

  研究者共评估了750例患者[220例HNF1A,245例GCK,54 例HNF4-α(HNF4A),21例HNF1-β(HNF1B),53 例1型糖尿病及157 例2型糖尿病患者]的hs-CRP水平。

  结果显示,HNF1A-MODY患者的hs-CRP水平[四分中位数(IQR)为0.3(0.1~0.6)mg/L]低于2型糖尿病[中位数(IQR)为1.40(0.60~3.45)mg/L;P<0.001]及1型糖尿病[中位数(IQR)为1.45(0.46~2.88)mg/L;P<0.001]、GCK-MODY[中位数(IQR)为0.60(0.30~1.80)mg/L;P<0.001]、HNF1B-MODY[中位数(IQR)为0.60(0.10~2.8)mg/L;P = 0.07]患者,hs-CRP<0.75mg/L可区分HNF1A-MODY和2型糖尿病,其敏感性为79%,特异性为70%(受试者工作特征曲线下面积=0.84)。

  链接:High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1900914, encodeId=3cb91900914b4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 19 08:53:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636460, encodeId=00b41636460d0, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon May 21 00:53:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759101, encodeId=34ec1e59101f7, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Feb 14 18:53:00 CST 2012, time=2012-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269559, encodeId=a31e1269559a7, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Fri Jul 15 14:53:00 CST 2011, time=2011-07-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1900914, encodeId=3cb91900914b4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 19 08:53:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636460, encodeId=00b41636460d0, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon May 21 00:53:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759101, encodeId=34ec1e59101f7, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Feb 14 18:53:00 CST 2012, time=2012-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269559, encodeId=a31e1269559a7, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Fri Jul 15 14:53:00 CST 2011, time=2011-07-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1900914, encodeId=3cb91900914b4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 19 08:53:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636460, encodeId=00b41636460d0, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon May 21 00:53:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759101, encodeId=34ec1e59101f7, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Feb 14 18:53:00 CST 2012, time=2012-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269559, encodeId=a31e1269559a7, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Fri Jul 15 14:53:00 CST 2011, time=2011-07-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1900914, encodeId=3cb91900914b4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 19 08:53:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636460, encodeId=00b41636460d0, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon May 21 00:53:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759101, encodeId=34ec1e59101f7, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Feb 14 18:53:00 CST 2012, time=2012-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269559, encodeId=a31e1269559a7, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Fri Jul 15 14:53:00 CST 2011, time=2011-07-15, status=1, ipAttribution=)]
    2011-07-15 rebeccajiejie

相关资讯

糖尿病治疗潜在新靶标:糖异生通路和PEPCK1

作者:孙国根 来源:医学论坛网   复旦大学生物医学研究院赵世民教授领衔的研究团队经三年多艰辛工作发现,通过调节人体内一种名叫“PEPCK1”的代谢酶可有效控制葡萄糖浓度,该项成果为糖尿病干预与治疗带来新的希望。国际顶尖学术期刊Cell系列刊物《分子细胞》(Molecular Cell)杂志7月8日刊登了这项最新研究成果。   科学家把人体内氨基酸等非葡萄糖营养物质转化为葡萄糖的过程叫做“糖异

科学家提出预测糖尿病新方法

日本一个研究小组日前发表论文说,在血糖测试之外加做糖化血红蛋白(HbA1c)测试,综合两项测试结果能比单独进行其中一项测试更准确地预测糖尿病。   来自日本筑波大学等机构的研究人员在新一期英国《柳叶刀》杂志网络版上刊登论文说,他们对6241人进行了为期5年的跟踪研究。研究对象包括4670名男性和1571名女性,他们的年龄介于24岁至82岁。所有研究对象接受研究之初都没有糖尿病既往史。

POP增加老年糖尿病危险

来源:医学论坛网   瑞典乌普萨拉的年长者脉管系统的前瞻性研究(PIVUS研究)表明,接触某些持久性有机污染物(POP)可显著增加老年人群未来患2型糖尿病的危险,尽管其发病病例数较少。该研究2011年6月23日在线发表于《糖尿病护理》(Diabetes care)杂志。   近期研究证实,主要蓄积于脂肪组织的POP和亲脂性化学物质,与2型糖尿病相关。不过,来自前瞻性研究的证据较为匮乏。该研究

全球糖尿病患者近3.5亿

全球慢性疾病代谢性危险因素负担合作组(GBMRFCDCG)根据近30年来空腹血糖水平的变化趋势,估计全世界现有约3.47亿成年人罹患糖尿病。该研究发表在《柳叶刀》6月25日在线版上(the Lancet. doi:10.1016/S0140-6736(11)60679-X)。 研究者收集、分析了199个国家和地区29年来的健康调查和流行病学研究数据,选择平均空腹血糖作为主要的血糖指标,其他血糖指

中国糖尿病外科治疗指南(草稿)

 本指南所指的糖尿病外科治疗只针对2型糖尿病,即在胰岛素抵抗的基础上进行性的胰岛素缺乏所致的糖尿病。本指南所指的外科治疗特指以限制食物摄入、减少食物吸收,或进行消化道重建从而改变肠-胰岛素轴激素分泌为目的的胃肠外科手术。1、背景糖尿病已经成为严重威胁人类健康的慢性疾病之一,由于糖尿病所引起的冠心病、肾病、视网膜病及神经病变等是造成患者致死、致残的主要原因。根据美国糖尿病协会(ADA)20

高敏CRP可区分糖尿病亚型

  英国一项研究表明,肝细胞核因子1-α-基因突变引起的年轻的成年发病型糖尿病(HNF1A - MODY)患者的高敏C反应蛋白(hs-CRP)水平低于其他类型的糖尿病患者,hs-CRP可能成为选择需进行诊断性HNF1A基因检测患者的生物标志物。该研究6月23日在线发表于《糖尿病护理》(Diabetes Care)杂志。   HNF1A-MODY常被误诊为1型糖尿病或2型糖尿病。新近研究发现,HN